Introduction
============

Preterm birth (prior to 37 weeks gestational age) is the principle cause of neonatal morbidity and mortality in the developed world. The United States has one of the highest rates of preterm births in the developed world, occurring in 12--13% of pregnancies (Goldenberg et al., [@B18]). Preterm deliveries account for 75% of perinatal mortality and surviving preterm infants are at risk for neurological, respiratory, and gastrointestinal complications (Goldenberg et al., [@B18]; Iams et al., [@B27]). Treatments such as intravaginal progesterone can be effective at maintaining pregnancies in women at increased risk for preterm labor. Tocolytic therapies to stop active labor do not delay parturition long enough to allow further fetal development, but do provide time for transportation to a hospital with a neonatal intensive care unit (Iams et al., [@B27]; Mackeen et al., [@B36]). However, tocolytics have a variety of side effects and there is not enough evidence of benefit to the infant to justify their use (Mackeen et al., [@B36]).

The mechanisms underlying the initiation of labor are poorly understood, which has limited progress on therapies to maintain pregnancy or stop preterm labor. The lack of a suitable animal model has limited progress toward understanding human parturition (Smith, [@B53]; Veliça et al., [@B60]; Hill et al., [@B23]; Nanjidsuren et al., [@B44]). The roles of the placenta and other reproductive tissues in parturition, as well as specific steroid and prostaglandin metabolites, differ considerably between mammalian species. Furthermore, the substrate specificities and expression levels of the aldo--keto reductase (AKR) isoforms differ considerably between species. Given the discrepancies in mechanism between species, this review will focus on the AKRs and their substrates and metabolites in human pregnancy.

Progestins play a critical role in human pregnancy, as demonstrated by the efficacy of progesterone in maintaining pregnancy and of the progesterone receptor (PR) antagonist mifepristone in terminating pregnancy and initiating labor (McGill and Shetty, [@B39]; Iams et al., [@B27]; Kulier et al., [@B33]). In other species, a decline in circulating progesterone levels, mediated by distinct pathways, precedes the onset of labor at term (Smith, [@B53]; Zakar and Hertelendy, [@B62]). However, serum progesterone levels do not decline during human pregnancies, suggesting that a different mechanism determines the timing of labor. The exact role of progesterone and its metabolites in determining the timing of human labor remains a mystery. Proposed pathways include paracrine regulation through increased myometrial expression of progesterone metabolizing enzymes and/or changes in PR expression. In addition to direct actions of progesterone, actions of its metabolites are likely involved. In particular, 5β-dihydroprogesterone (5β-DHP) inhibits myometrial contractility (Kubli-Garfias et al., [@B32]; Grazzini et al., [@B19]; Thornton et al., [@B59]; Sheehan, [@B50]). The activities of human AKR1D1 and AKR1Cs suggest they play critical roles in mediating these processes.

Prostaglandins (PG) are also key mediators of parturition. Upregulation of PGH~2~ synthase 2 occurs late in pregnancy, resulting in an increase in the synthesis of prostaglandins, particularly the PGF~2~ isomers (Mijovic et al., [@B40]; Slater et al., [@B52]; Mitchell et al., [@B42]; Lee et al., [@B35]). Activation of the F prostanoid (FP) receptor by prostaglandins stimulates cervical ripening and the initiation of labor (Kelly et al., [@B31]). AKR1B1 and AKR1C3 are the enzymes that form the PGF~2~ isomers in humans.

AKR1D1 in the Maintenance of Pregnancy
======================================

AKR1D1, human 5β-reductase, catalyzes the formation of 5β-androstanes and 5β-pregnanes and contributes to the formation of bile acids in the liver (Charbonneau and Luu-The, [@B10]; Chen et al., [@B11]). Of particular relevance to pregnancy, AKR1D1 catalyzes the conversion of progesterone to 5β-DHP (Figure [1](#F1){ref-type="fig"}; Charbonneau and Luu-The, [@B10]; Chen et al., [@B11]). 5β-DHP may be a key mediator of the pregnancy maintaining effects of progesterone. While levels of progesterone do not decrease during the final week of pregnancy, levels of 5β-pregnanes decline starting in week 31 (Hill et al., [@B22]). This decline appears to be largely the result of decreased 5β-reduction, although increased downstream metabolism may also occur. Although 5β-DHP was proposed to bind directly to the oxytocin receptor and antagonize oxytocin binding (Grazzini et al., [@B19]), others have not been able to replicate this finding (Burger et al., [@B7]; Astle et al., [@B3]). 5β-DHP could also inhibit contractions through activation of the pregnane X receptor (Mitchell et al., [@B42]), allosteric modulation of the GABA receptor (Putnam et al., [@B48]), or through some as yet unknown mechanism. Although the mechanism is uncertain, it is clear that 5β-DHP limits myometrial contractility; it is significantly more potent than progesterone at inhibiting the contraction of myometrial cells *in vitro* (Kubli-Garfias et al., [@B32]; Thornton et al., [@B59]).

![**Progesterone metabolism by AKR1D1 and AKR1Cs in pregnancy**. AKR1D1 is likely to inhibit myometrial contractions through formation of 5β-dihydroprogesterone, while AKR1C1, AKR1C2, and AKR1C3 are likely to stimulate contractions through the elimination of progesterone and 5β-dihydroprogesterone. AKR1D1 and the AKR1Cs might also contribute to formation of neuroactive progesterone metabolites. The AKR1Cs would have similar activities toward 5α-dihydroprogesterone (not shown).](fphar-02-00092-g001){#F1}

Elevated expression of AKR1D1 likely helps maintain human pregnancy. The placenta appears to be the major site of AKR1D1 expression, although it is also expressed in the myometrium (Sheehan et al., [@B51]). The decline in 5β-DHP levels during labor are accompanied by a significant decline in AKR1D1 mRNA levels. The effect was particularly pronounced in the myometrium, which demonstrated a sevenfold reduction in AKR1D1 levels (Sheehan et al., [@B51]). Decreased synthesis of relaxatory pregnanes by AKR1D1 may play an important role in the onset of labor.

AKR1D1 exhibits potent substrate inhibition by Δ^4^-ene steroids due to binding in a non-productive conformation (Di Costanzo et al., [@B12]; Faucher et al., [@B16]; Chen et al., [@B11]), suggesting a second mechanism for the regulation of its activity. The presence of other Δ^4^-ene steroids, particularly 11-deoxy-corticosterone and 4-androstene-3,17-dione (Chen et al., [@B11]), would be anticipated to potently decrease the formation of 5β-DHP by AKR1D1. 4-Androstenedione levels are slightly elevated during labor, while levels of its aromatase product estrone are very high during labor (Hill et al., [@B23]). Given the permissive ligand binding pocket of AKR1D1 (Di Costanzo et al., [@B12]; Faucher et al., [@B16]), it is likely that steroids that are not substrates, including estrogens, will serve as inhibitors. This inhibition might contribute to the induction of labor by estrogens.

Although it is found in higher concentrations than 5β-DHP throughout pregnancy, 5α-DHP formation does not appear to contribute to the timing of labor. 5α-DHP is completely unable to inhibit myometrial contractility *in vitro* (Kubli-Garfias et al., [@B32]). Ratios of progesterone to 5α-DHP remain constant throughout pregnancy and it appears that expression levels of 5α-reductase enzymes remain elevated throughout pregnancy (Hill et al., [@B23]). Much of the work that has investigated 5α-reduced pregnanes in pregnancy has focused on their neuroendocrine effects, including their anxiolytic and anesthetic effects in the mother, and their important role in protecting the developing nervous system of the neonate (Amin et al., [@B1]; Hirst et al., [@B25]; Hill et al., [@B24]). Both 5α- and 5β-progestins, particularly allopregnanolone and pregnanolone, act as allosteric modulators of GABA~A~ receptors (Reddy, [@B49]).

Ketosteroid Reduction by AKR1Cs in Parturition
==============================================

Members of the AKR1C subfamily are likely to help initiate labor by catalyzing the formation of inactive progestin metabolites, leading to paracrine suppression of PR signaling (Figure [1](#F1){ref-type="fig"}). AKR1C1, AKR1C2, and AKR1C3 eliminate progesterone, 5α-DHP, and 5β-DHP through their 20-ketosteroid reductase activities (Penning et al., [@B47]; Jin et al., [@B28]). Furthermore, they possess substantial 3-ketosteroid reductase activities that provide another pathway for the metabolism of 5α-DHP and 5β-DHP (Jin et al., [@B28]). The 20α-, 3α-, and 3β-hydroxy-progestin products of AKR1C enzymes have reduced tocolytic activities and are substrates for elimination through glucuronidation or sulfation. The 3-hydroxy products, such as pregnanolone and allopregnanolone, are neuroactive and could contribute to analgesic and anxiolytic effects in the mother and neuroprotection of the fetus (Steckelbroeck et al., [@B56]; Amin et al., [@B1]; Hirst et al., [@B25]; Reddy, [@B49]; Hill et al., [@B24]). The stereochemistry for the reduction of 3-ketosteroids varies between AKR1C isoforms and between 5α-DHP and 5β-DHP, while reduction of the ketone at the 20 position exclusively forms the 20α-stereoisomer (Jin et al., [@B28]).

AKR1C1, AKR1C2, and AKR1C3 are expressed in reproductive tissues, including the placenta, myometrium, and cervix (Nishizawa et al., [@B45]; Andersson et al., [@B2]; Lee et al., [@B34]; Hevir et al., [@B21]). Placental tissues obtained from pregnancies at term reduce progesterone to 20α-hydroxyprogesterone at five times the rate of placentas from the first trimester and there is a further increase in activity with the onset of labor (Milewich et al., [@B41]; Diaz-Zagoya et al., [@B13]). It is not known whether expression levels of the AKR1C enzymes correspond to the observed activity. Expression of mRNA encoding AKR1C1 is elevated in the myometrium during spontaneous, but not oxytocin induced, labor (Lee et al., [@B34]). AKR1C1 has the highest catalytic activity toward 20-ketosteroids, and this enzyme likely plays an important role in the inactivation of myometrial progesterone during spontaneous labor (Penning et al., [@B47]; Jin et al., [@B28]). Placental expression of AKR1C3 during pregnancy has primarily been examined in the context of its prostaglandin metabolizing effects and is discussed below. AKR1C2 expression in placenta is the lowest of the three peripheral AKR1C isoforms (Nishizawa et al., [@B45]) and the contribution of AKR1C2 to parturition may be less critical than AKR1C1 and AKR1C3.

Andersson et al. ([@B2]) used intact tissues from combined hysterectomy and cesarean section to examine the role of AKR mediated 20-ketosteroid reductase activity in cervical ripening. They observed mRNA transcripts corresponding to AKR1C1, AKR1C2, and AKR1C3 in cervix, with AKR1C1 exhibiting the highest expression. Cervical tissue from patients in active labor exhibited considerably faster progesterone 20-ketosteroid reduction relative to patients who were not in labor. However, cervical expression of mRNA for the three AKR1C isoforms did not change with labor onset. The increased reductase activity was proposed to result from decreased expression of type 2 17β-hydroxysteroid dehydrogenase, which catalyzes the opposing oxidation reaction (Andersson et al., [@B2]).

Prostaglandin Synthase Activities of AKRs
=========================================

Prostaglandins also regulate parturition. A critical signal in determining the timing of parturition is the release of calcium due to FP receptor activation. Unlike PGE~2~, which has receptors that inhibit contractions and others that induce them, PGF~2α~ has only labor promoting effects (Brodt-Eppley and Myatt, [@B6]). The principle phenotype of FP receptor knockout mice is the inability to deliver young at term, which is rescued by the administration of oxytocin (Sugimoto et al., [@B57]; Kawamata et al., [@B30]). A selective FP receptor antagonist inhibits myometrial cell contractility *in vitro* (Friel et al., [@B17]). Regulation of FP signaling is partially via control of its expression levels and partially through the levels of its PGF~2~ ligands, which are determined by the expression of PGH~2~ synthase 2, and AKR1B1 and/or AKR1C3 (Figure [2](#F2){ref-type="fig"}; Mijovic et al., [@B40]; Slater et al., [@B52]; Mitchell et al., [@B42]; Lee et al., [@B35]; Smith et al., [@B54]; Watanabe, [@B61]). Transcript for the FP receptor is suppressed throughout pregnancy, declining with gestational age until immediately before the initiation of labor, when expression levels spike (Brodt-Eppley and Myatt, [@B6]; Olson et al., [@B46]). In sheep corpus luteum and rat myometrium, expression of the FP receptor is upregulated by estradiol administration, while progesterone has a suppressive effect, suggesting that steroids may regulate receptor levels during pregnancy (Hoyer et al., [@B26]; Dong and Yallampalli, [@B14]).

![**Prostaglandin metabolism by AKR1C3 and AKR1B1 in pregnancy**. Both AKR1C3 and AKR1B1 form PGF~2α~ from PGH~2~, while AKR1C3 also forms 9α,11β-PGF~2~ and AKR1B1 may also contribute to the formation of PGD~2~. Both PGF~2~ isomers will stimulate myometrial contractions through activation of the FP receptor.](fphar-02-00092-g002){#F2}

The traditional ligand for the FP receptor is PGF~2α~, although its stereoisomer 9α,11β-PGF~2~ is also a potent ligand (Mitchell et al., [@B42]). Levels of PGF~2α~ in amniotic fluid are low throughout the first 36 weeks of pregnancy before rising during the last few weeks of pregnancy (Lee et al., [@B35]). Samples from patients at term indicated a substantial increase in PGF~2α~ from no labor (250 pg/mL) to early labor (640 pg/mL) and advanced labor (4300 pg/mL), which was far greater than the increase in PGE~2~ levels. These measurements were performed with a commercial immunosorbent assay with an antibody against PGF~2α~, but cross-reactivity with 9α,11β-PGF~2~ was not ruled out. Similar levels of 9α,11β-PGF~2~ (400 pg/mL) were detected in amniotic fluid samples from patients undergoing labor at term using an assay with an antibody that had limited cross-reactivity with PGD~2~, but not PGF~2α~, suggesting that both isomers may play an important role in labor (Mitchell et al., [@B42]). Elevated levels of 9α,11β-PGF~2~ (200 pg/mL) were detected in patients at term who were not undergoing labor, while levels of this isomer were suppressed in patients prior to 36 weeks, including those undergoing preterm labor. The absence of increased 9α,11β-PGF~2~ in preterm labor could be the result of low levels of PGD~2~ synthase or low AKR1C3 activity.

The enzymes responsible for the increased synthesis of PGF~2~ products at term have not been conclusively identified. However, both of the proposed prostaglandin F synthases are aldo--keto reductases (Smith et al., [@B54]; Watanabe, [@B61]). AKR1C3 forms both PGF~2~ isoforms. AKR1C3 has substantially higher catalytic activity for the reduction of PGD~2~ to 9α,11β-PGF~2~ relative to its other endogenous substrates, while the conversion of PGH~2~ to PGF~2α~ is also faster than for its steroid substrates (Matsuura et al., [@B38]; Suzuki-Yamamoto et al., [@B58]). Involvement of the AKR1B family has only recently been recognized, with the bovine AKR1B5 isoform first shown to synthesize PGF~2α~ (Madore et al., [@B37]). In humans, AKR1B1 exhibits a higher catalytic activity for the conversion of PGH~2~ to PGF~2α~ than AKR1C3, but it is not involved in the formation of 9α,11β-PGF~2~ (Kabututu et al., [@B29]). In addition to synthesizing PGF~2α~, a recent report indicates that in the absence of cofactor, AKR1B1 can catalyze the rearrangement of PGH~2~ to form PGD~2~; AKR1C3 did not exhibit this activity (Nagata et al., [@B43]).

AKR1B1 and AKR1C3 are expressed in reproductive tissues during pregnancy and both likely synthesize PGF~2~ during pregnancy. Both AKR1B1 and AKR1C3 were cloned based on placental DNA libraries (Grundmann et al., [@B20]; Dufort et al., [@B15]). Most of the early work on AKR1B1 focused on its role in regulating glucose metabolism, although it has many additional endogenous substrates (Srivastava et al., [@B55]). Its roles in prostaglandin signaling have only recently been described (Kabututu et al., [@B29]; Bresson et al., [@B4]). AKR1C3 also catalyzes the reduction of a wide variety of substrates in addition to prostaglandins (Matsuura et al., [@B38]; Suzuki-Yamamoto et al., [@B58]; Byrns et al., [@B8]).

Expression of AKR1B1 and AKR1C3 were recently examined at the mRNA and protein levels in placenta (Breuiller-Fouché et al., [@B5]). Based on immunohistochemistry, both enzymes were expressed throughout the fetal membranes, but the highest expression was in chorionic trophoblasts and in decidual stromal cells. Western blot and quantitative RT-PCR indicated that AKR1B1 was primarily expressed in the choriodecidua, while AKR1C3 exhibited similar expression levels in both choriodecidua and amnion. Lipopolysaccharide stimulation did not upregulate either protein, suggesting that their expression levels do not contribute to preterm labor induced by intrauterine infection. Changes in placental expression of these enzymes over the course of pregnancy have not been examined.

Conclusion
==========

Further research is needed to understand the contribution of the AKRs to the induction of normal labor. Furthermore, very little is known about the roles of the AKRs in mediating signaling during preterm labor, which may be very different than what occurs at term. Evidence supports a role for declining placental and myometrial AKR1D1 expression in the initiation of labor. Increased paracrine inactivation of progestins by AKR1Cs may also be an important step in parturition. Formation of increased levels of PGF~2~ isomers stimulates labor, although a major unresolved question is whether changes in the placental expression of AKR1B1 and/or AKR1C3 contribute to this effect. Changes in levels of steroid and prostaglandin products could also result from changes in other enzymes involved in upstream and downstream metabolism.

Although the contribution of AKR1C3 to labor initiation has not been the subject of much research, its enzymatic activities suggest an important role. Each of its enzymatic activities has the potential to contribute to the initiation of parturition. AKR1C3 can eliminate progesterone and its 5α- and 5β-reduced products and can synthesize estradiol and both prostaglandin F~2~ isomers (Byrns et al., [@B8]; Jin et al., [@B28]). Furthermore, it is potently inhibited by the tocolytic drug indomethacin (Byrns et al., [@B9]). It is expressed in several reproductive tissues during pregnancy, although it is not known whether expression levels change, except in the cervix where it does not (Nishizawa et al., [@B45]; Andersson et al., [@B2]; Breuiller-Fouché et al., [@B5]). Further investigation into the role of AKR1C3 in parturition is needed.

It remains to be seen whether targeting AKRs can have benefits in pregnancy. AKR1D1 inhibitors might be useful for inducing cervical ripening or given along with oxytocin for the initiation of labor. Inhibitors of the AKR1B and AKR1C enzymes might have benefits for the maintenance of pregnancy or for tocolysis. However, a number of potential pitfalls make developing pharmacotherapies based on AKRs challenging. The lack of an animal model makes testing these targets challenging. Given that mammals have distinct mechanisms of parturition and AKR substrate specificities, it is not clear that effects in animal models will apply to human pregnancies. Another potential issue is that the AKR1C and AKR1D enzymes contribute to the synthesis of neuroactive steroids, such as allopregnanolone and pregnanolone. Given the neuroprotective effects of these steroids, inhibition of these enzymes in the fetal compartment may be undesirable.
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